LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Harvard Bioscience Inc

Fechado

SetorSaúde

0.54 -8.47

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.53

Máximo

0.6

Indicadores-chave

By Trading Economics

Rendimento

1.1M

-1.2M

Vendas

141K

21M

Margem de lucro

-5.978

Funcionários

330

EBITDA

1M

1.2M

Dividendos

By Dow Jones

Próximos Ganhos

12 de mar. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.9M

24M

Abertura anterior

9.01

Fecho anterior

0.54

Sentimento de Notícias

By Acuity

17%

83%

23 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Harvard Bioscience Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de fev. de 2026, 23:47 UTC

Ações em Alta

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 de fev. de 2026, 22:59 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Grab Holdings to Buy U.S.-Based Stash Financial

11 de fev. de 2026, 23:54 UTC

Ganhos

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 de fev. de 2026, 23:50 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

11 de fev. de 2026, 23:50 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 de fev. de 2026, 23:49 UTC

Ganhos

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 de fev. de 2026, 23:45 UTC

Ganhos

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 de fev. de 2026, 23:42 UTC

Ganhos

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 de fev. de 2026, 23:41 UTC

Ganhos

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 de fev. de 2026, 23:40 UTC

Ganhos

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 de fev. de 2026, 23:35 UTC

Conversa de Mercado

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 de fev. de 2026, 23:18 UTC

Conversa de Mercado

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 de fev. de 2026, 23:14 UTC

Conversa de Mercado

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 de fev. de 2026, 22:59 UTC

Ganhos

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 de fev. de 2026, 22:58 UTC

Ganhos

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 de fev. de 2026, 22:57 UTC

Ganhos

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 de fev. de 2026, 22:54 UTC

Ganhos

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 de fev. de 2026, 22:53 UTC

Ganhos

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 de fev. de 2026, 22:47 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 de fev. de 2026, 22:47 UTC

Ganhos

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 de fev. de 2026, 22:23 UTC

Ganhos

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 de fev. de 2026, 22:22 UTC

Ganhos

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 de fev. de 2026, 22:22 UTC

Ganhos

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 de fev. de 2026, 22:19 UTC

Ganhos

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 de fev. de 2026, 22:18 UTC

Ganhos

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 de fev. de 2026, 22:16 UTC

Ganhos

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparação entre Pares

Variação de preço

Harvard Bioscience Inc Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.3 / 0.3401Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

No Evidence

Longo Prazo

No Evidence

Sentimento

By Acuity

23 / 352 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat